Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | GBA1 | P04062 | 1/20 | 0.41 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.39 |
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | CCR3 | P51677 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27514317 | 0.98 | POLB (0.44) | POLBGBA1SLC18A3NOS3NOS1 | |
| SCHEMBL1929149 | 0.94 | POLB (0.43) | POLBGBA1NOS3NOS1NOS2 | |
| SCHEMBL1930265 | 0.87 | GBA1 (0.47) | POLBGBA1CCR3 | |
| SCHEMBL6567840 | 0.81 | SLC18A2 (0.46) | — | |
| SCHEMBL7535902 | 0.79 | POLB (0.42) | POLBGBA1SLC18A3HSD11B1 | |
| SCHEMBL7535898 | 0.79 | POLB (0.42) | POLBGBA1SLC18A3HSD11B1 | |
| SCHEMBL5722050 | 0.78 | SLC18A3 (0.41) | SLC18A3 | |
| SCHEMBL29023326 | 0.77 | TSHR (0.45) | — | |
| SCHEMBL6570849 | 0.74 | SLC18A2 (0.47) | — | |
| SCHEMBL5411582 | 0.74 | POLB (0.41) | POLBGBA1NOS3NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7456183-B2 | Guanidino compounds | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-11-25 | — | — | US | claimed |
| US-7189727-B2 | Guanidino compounds | CHIRON CORPORATION (US) | 2007-03-13 | — | — | US | claimed |
| EP-1385823-B1 | GUANIDINO COMPOUNDS AS MELANOCORTIN-4 RECEPTOR (MC4-R) AGONISTS | CHIRON CORP (US) | 2006-12-13 | — | — | EP | claimed |
| US-6960582-B2 | Guanidino compounds | CHIRON CORPORATION (US) | 2005-11-01 | — | — | US | claimed |
| US-20050124652-A1 | Guanidino compounds | BOYCE RUSTUM (US) | 2005-06-09 | — | — | US | claimed |
| US-20050038027-A1 | Novel guanidino compounds | CHIRON CORPORATION | 2005-02-17 | — | — | US | claimed |
| US-20040248895-A1 | Novel guanidino compounds | CHU DANIEL (US) | 2004-12-09 | — | — | US | claimed |
| EP-1478626-A2 | GUANIDINO COMPOUNDS | CHIRON CORPORATION (US) | 2004-11-24 | — | — | EP | claimed |
| US-6716840-B2 | AGONISTS OF THE MELANOCORTIN-4 RECEPTOR (?MC-4R?); USEFUL TREATING OBESITY AND TYPE 2 DIABETES | CHIRON CORPORATION | 2004-04-06 | — | — | US | claimed |
| US-20040024211-A1 | Novel guanidino compounds | CHIRON CORPORATION | 2004-02-05 | — | — | US | claimed |
| US-20030195187-A1 | Guanidino compounds | CHIRON CORPORATION | 2003-10-16 | — | — | US | claimed |
| WO-2003066597-A2 | GUANIDINO COMPOUNDS | CHIRON CORPORATION (US) | 2003-08-14 | — | — | WO | claimed |
| US-8003699-B2 | Amide compound and use thereof for controlling plant diseases | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-08-23 | — | — | US | disclosed |
| US-7956010-B2 | Amide compound and use thereof for controlling plant diseases | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-06-07 | — | — | US | disclosed |
| US-7858641-B2 | melanocortin-4 receptor (MC4-R) agonists such as (3R,5S)-N-(2-{2-[2-fluoro-4-(methyloxy)phenyl]ethyl}-1-oxo-1,2-dihydroisoquinolin-6-yl)-3,5-dimethyl-N'-[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]piperazine-1-carboximidamide, used for the treatment of obesity or diabetes | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-7858631-B2 | Substituted pyrido [2,3-d] pyrimidinone compounds | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-12-28 | — | — | US | disclosed |
| EP-0205079-A2 | Acid disulfimide triphenodioxazine dyes | BAYER AG (DE) | 1986-12-17 | — | — | EP | disclosed |
| EP-0205080-A2 | Triphenodioxazine-disulfimide reactive dyes | BAYER AG (DE) | 1986-12-17 | — | — | EP | disclosed |
| EP-0204245-A2 | Reactive dyes | BAYER AG (DE) | 1986-12-10 | — | — | EP | disclosed |
| EP-0190603-A2 | Aminoalkylenesulfone-triphenedioxazine dyes | BAYER AG (DE) | 1986-08-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038027-A1 | Novel guanidino compounds | MC4R, MC3R, GCKR | POLB 2657/4885GBA1 1181/4885SLC18A3 3041/4885 |
| US-20030195187-A1 | Guanidino compounds | MC4R, MC2R, GPR4 | POLB 3791/4885GBA1 1028/4885SLC18A3 1126/4885 |
| US-20040024211-A1 | Novel guanidino compounds | MC4R, MC5R, MC3R | POLB 3486/4885GBA1 3079/4885SLC18A3 1985/4885 |
| US-20050124652-A1 | Guanidino compounds | MC4R, MC2R, GPR4 | POLB 3791/4885GBA1 1028/4885SLC18A3 1126/4885 |
| US-20040248895-A1 | Novel guanidino compounds | MC4R, MC5R, MC3R | POLB 3859/4885GBA1 2964/4885SLC18A3 2433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.